Rocket Pharmaceuticals, Inc.
RCKT
$4.87
$0.142.96%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.49% | 24.56% | 1.04% | 1.16% | -1.12% |
| Total Depreciation and Amortization | -6.10% | 35.62% | 8.77% | 32.61% | 22.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.41% | -12.21% | 39.26% | -4.10% | 51.89% |
| Change in Net Operating Assets | -83.19% | -491.81% | 20.53% | -0.64% | -94.70% |
| Cash from Operations | 25.78% | 3.23% | 9.03% | 1.87% | -60.00% |
| Capital Expenditure | 74.11% | 103.40% | 97.41% | 82.11% | 93.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 197.19% | 16.22% | -44.73% | -255.58% | 72.41% |
| Cash from Investing | 196.18% | 18.62% | -42.90% | -265.65% | 73.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 46,664.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -138.07% | -85.95% | -- | 46,664.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.38% | 59.78% | -610.00% | -451.53% | 157.75% |